0710-0072

Seraseq™ Tumor Mutation DNA Mix v2 (AF7) LC

/globalassets/images/product-pages/seraseq_product.jpg
  • Size

    1 × 25 µL

  • List Price

    Contact Us

  • Unit

    EA

  • Inventory Status

    In Stock

Description

The Seraseq Tumor Mutation DNA Mix v2 (AF7) LC is a multiplexed mixture of actionable biosynthetic DNA targets precisely blended with a single, well-characterized genomic background to an allelic frequency of 7%, offered in a low concentration (LC) at 5 ng/μL. Designed to assess the overall performance of your somatic mutation assay by next-generation sequencing (NGS), this unique product includes a wide range of single nucleotide variants (SNVs), insertion-deletion mutations (indels), and structural variants (SVs).

  • Single-vial format for daily run use
  • 40 unique multiplexed variants across 28 genes (see table on right)
    • 20 SNVs
    • 5 SNVs that are part of homopolymers
    • 13 indels
    • 2 SVs 
  • Mutation targets quantitated with digital PCR
  • Well-characterized GM24385 human genomic DNA as background ‘wild-type’ material
  • Manufactured in cGMP compliant, ISO 9001 and ISO 13485 certified facilities


View the Product Sheet
 for a detailed list of variants.

The Seraseq Tumor Mutation DNA Mix v2 (AF7) LC is formulated for use with targeted next-generation sequencing (NGS) assays that detect mutations in key oncogenes and tumor suppressor genes. The Seraseq Tumor Mutation DNA Mix v2 (AF7) LC is intended as a quality reference material for translational and disease research testing to monitor library preparation, sequencing, and variant allele detection under a given set of bioinformatics pipeline parameters.

For research use only. Not for use in diagnostic procedures.